Source: yahoo_news
Source ID: yahoo:894cc11cb92cd49135547d22d405178f:TRDA
URL: https://finance.yahoo.com/healthcare/articles/independent-safety-data-monitoring-committee-110000198.html?.tsrc=rss
Symbol: (TRDA)
Published: 2026-10-14 07:00:00 EDT
Time precision: minute
Title: Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascendin